N6-Cyclohexyladenosine
N6-Cyclohexyladenosine structure
|
Common Name | N6-Cyclohexyladenosine | ||
|---|---|---|---|---|
| CAS Number | 36396-99-3 | Molecular Weight | 349.38500 | |
| Density | 1.71g/cm3 | Boiling Point | 675.2ºC at 760mmHg | |
| Molecular Formula | C16H23N5O4 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 362.1ºC | |
Use of N6-CyclohexyladenosineN6-Cyclohexyladenosine is a selective A1 receptor agonist (EC50 = 8.2 nM). IC50 value: 8.2 nM (EC50)Target: A1 receptorin vivo: N6-Cyclohexyladenosine exerts anticonvulsant effects and protects against neuronal death. CHA was also found to inhibit the pressor effects of lumbar sympathetic nerve stimulation in rats. |
| Name | (2R,3R,4S,5R)-2-(6-(Cyclohexylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol |
|---|---|
| Synonym | More Synonyms |
| Description | N6-Cyclohexyladenosine is a selective A1 receptor agonist (EC50 = 8.2 nM). IC50 value: 8.2 nM (EC50)Target: A1 receptorin vivo: N6-Cyclohexyladenosine exerts anticonvulsant effects and protects against neuronal death. CHA was also found to inhibit the pressor effects of lumbar sympathetic nerve stimulation in rats. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.71g/cm3 |
|---|---|
| Boiling Point | 675.2ºC at 760mmHg |
| Molecular Formula | C16H23N5O4 |
| Molecular Weight | 349.38500 |
| Flash Point | 362.1ºC |
| Exact Mass | 349.17500 |
| PSA | 125.55000 |
| LogP | 0.25540 |
| Index of Refraction | 1.787 |
| Storage condition | 2-8℃ |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
CAS#:2004-06-0
CAS#:108-91-8
CAS#:38583-85-6![9-[2,3,5-TRI-O-ACETYL-BETA-D-RIBOFURANOSYL]-2,6-DICHLOROPURINE Structure](https://image.chemsrc.com/caspic/019/3056-18-6.png)
CAS#:3056-18-6|
An adenosine kinase inhibitor, ABT-702, inhibits spinal nociceptive transmission by adenosine release via equilibrative nucleoside transporters in rat.
Neuropharmacology 97 , 160-70, (2015) Adenosine kinase (AK) inhibitor is a potential candidate for controlling pain, but some AK inhibitors have problems of adverse effects such as motor impairment. ABT-702, a non-nucleoside AK inhibitor,... |
|
|
IL-6, A1 and A2aR: a crosstalk that modulates BDNF and induces neuroprotection.
Biochem. Biophys. Res. Commun. 449(4) , 477-82, (2014) Several diseases are related to retinal ganglion cell death, such as glaucoma, diabetes and other retinopathies. Many studies have attempted to identify factors that could increase neuroprotection aft... |
|
|
The interaction of adenosine and morphine on pentylenetetrazole-induced seizure threshold in mice.
Neuropharmacology 72 , 1-8, (2013) Adenosine agonists or low doses of morphine exert anti-convulsant effects in different models of seizures. On the other hand, a tight interaction has been reported between morphine and adenosine in va... |
| N6-Cyclohexyladenosine |